Monash IVF Group (MVF) Guidance summary
Event summary combining transcript, slides, and related documents.
Guidance summary
6 Jun, 2025Opening remarks and agenda
Provided an update on anticipated Underlying NPAT for the year ending 30 June 2025, revising previous guidance.
Guidance on key objectives
FY25 Underlying Group NPAT is now expected to be approximately $27.5m, down from prior guidance of $30.0m–$31.0m.
Non-regular items for FY25 will include costs related to the Brisbane incident, legal, and advisory expenses.
Market trends and strategic opportunities
Softer market and operating conditions in March and April 2025 impacted performance across all geographic markets.
May 2025 showed improved operating conditions, but not enough to offset earlier months' impact.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Monash IVF Group
- FY26 NPAT guidance lowered to $17–18m as market slows, but market share and international growth rise.MVF
Trading update - Underlying NPAT was $10.4M, down 34%, with international and genetics growth offsetting IVF decline.MVFH1 2026
- FY2025 saw revenue and EBITDA growth, lower NPAT, and no dividend, with renewal and digital focus.MVFAGM 2025
- Revenue and EBITDA grew, but NPAT declined; FY26 outlook cautious with dividend resumption planned.MVFH2 2025
- Record profit, global expansion, and Vision 2026 defined a year of growth amid class action impact.MVFAGM 2024
- Underlying NPAT up 17.4% to AUD 29.9m; revenue up 19.4% despite AUD 32.6m class action loss.MVFH2 2024
- Double-digit revenue and EBITDA growth, rising market share, and strong FY25 outlook.MVFH1 2025